Amphotericin B liposomal
آمفوتریسین B لیپوزومال
🦠 Antiinfectives For Systemic UsePolyene antifungal
Market / country: 🇺🇸 USA
AmBisome (US)
🧮 Dose calculator
Invasive fungal infection (aspergillosis, candidaemia, cryptococcosis) — hospital · Regimen source: FDA AmBisome · Dosage and Administration
- • Not interchangeable mg-for-mg with other amphotericin B products. Infuse over about 120 min (60 min if tolerated). Reconstitute with sterile water only, not saline. FDA AmBisome · Dosage and Administration
Enter age and weight.
🛡️ Safety & information
Contraindications
- ⛔ Hypersensitivity to amphotericin B or any component, unless the physician judges benefit outweighs risk. FDA AmBisome · Contraindications
Formulations
- 50 mg vial (4 mg/mL after reconstitution) — powder for injection 🇺🇸 USA FDA AmBisome · Dosage and Administration — Reconstitution
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA AmBisome · Pregnancy
“There have been no adequate and well-controlled studies of Am B isome in pregnant women.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA AmBisome · Nursing Mothers
“Due to the potential for serious adverse reactions in breastfed infants, a decision should be made whether to discontinue nursing or whether to discontinue the drug, taking into account the importance of the drug to the mother.”
- 👶 ChildrenSafety not established
Label: safety and effectiveness in children have not been established. FDA AmBisome · Pediatric Use
“Safety and effectiveness in pediatric patients below the age of one month have not been established (See DESCRIPTION OF CLINICAL STUDIES - Empirical Therapy in Febrile Neutropenic Patients and DOSAGE AND ADMINISTRATION ).”
- 👴 Older adultsNo data
The source for this drug has no section for this group.
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)NDA050740
- DailyMed (FDA label)FDA AmBisome
- MedlinePlus (NIH)Amphotericin B Injection
- WHO ATC/DDDJ02AA01
- Darooyab (Iran)Amphotericin-B
🇮🇷 Registered in Iran Darooyab · G-694/Amphotericin-B
Dosage forms with Iranian generic codes, per Darooyab.
- 09765 · AMPHOTERICIN-B 100MG/50ML VIAL · ویال آمفوتریسین بی ۱۰۰ میلیگرم / ۵۰ میلیلیتر
- 00079 · AMPHOTERICIN-B 50MG/20ML VIAL · ویال آمفوتریسین بی ۵۰ میلیگرم / ۲۰ میلیلیتر
- 17094 · AMPHOTERICIN-B LIPOSOMAL VIAL · ویال آمفوتریسین بی لیپوزومال
- 22891 · AMPHOTERICIN B NANOLIPOSOMAL GEL TOPICAL 0.4 % 15 g · ژل موضعی آمفوتریسین B نانولیپوزومال ۰٫۴ درصد ۱۵ گرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA AmBisome · Dosage and Administration — ReconstitutionFDA AmBisome · Dosage and AdministrationFDA AmBisome · ContraindicationsFDA AmBisome · PregnancyFDA AmBisome · Nursing MothersFDA AmBisome · Pediatric UseFDA AmBisome · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-694/Amphotericin-B
- Clinical review⚠ Unverified